Journal
CARBOHYDRATE POLYMERS
Volume 272, Issue -, Pages -Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.carbpol.2021.118530
Keywords
Colon targeted drug delivery; Inflammatory bowel disease; Polysaccharide; Nanocarrier
Categories
Funding
- National Natural Science Foundation of China [81572989]
- International Academic Cooperation of Science and Technology Committee of Shanghai, China [18430721100]
Ask authors/readers for more resources
Polysaccharide-based nanocarriers can help reduce the side effects of drugs used for treating inflammatory bowel disease (IBD) by targeting the colon and enhancing their bioavailability. Polysaccharides also play a role in alleviating IBD through their anti-inflammatory and intestinal microecological regulatory effects.
Drugs such as immunosuppressants and glucocorticoids used for the treatment of inflammatory bowel disease (IBD) have certain troubling side effects. Polysaccharide-based nanocarriers with high safety and bioavailability are often used in the construction of colon-targeted drug nanodelivery systems (DNSs). It can help the drug resist the harsh environment of gastrointestinal tract, improve stability and concentrate on the intestinal inflammation regions as much as possible, which effectively reduces drug side effects and enhances its bioavailability. Certain polysaccharides, as prebiotics, can not only endow DNSs with the ability to target the colon based on enzyme responsive properties, but also cooperate with drugs to alleviate IBD due to its good anti-inflammatory activity and intestinal microecological regulation. The changes in the gastrointestinal environment of patients with IBD, the colon-targeted drug delivery process of polysaccharide-based nanocarriers and its synergistic treatment mechanism for IBD were reviewed. Polysaccharides used in polysaccharide-based nanocarriers for IBD were summarized.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available